Trump, who is in the Philippines on a diplomatic trip, announced his intention to nominate Azar on Twitter by saying he would "be a star for better healthcare and lower drug prices". For those opposed to the path Trump has been taking Health and Human Services, Alex Azar symbolizes yet another attack on the progress made by the Affordable Care Act with his policy preferences aimed at undercutting and reversing numerous ACA's provisions. In 2012, he became the president of the company's affiliate for North America, Lilly USA.
Azar's nomination must be approved by the U.S. Senate, which is controlled by Trump's fellow Republicans. His supporters say that Azar's understanding of the complicated dynamics behind pharmaceuticals pricing will give him an advantage in figuring out how to make drugs more affordable.
Azar's grandfather immigrated from Lebanon 100 years ago. "He also appreciates the need to have access to healthcare data and interoperability of health information systems". With the Alex Azar pick, Donald Trump is choosing someone with experience in both the industry in general and the agency in particular he is meant to lead. Azar joined Lilly in 2007 as a senior vice president of global corporate affairs and communications.
Four things to watch: Duke vs. Michigan State
A year ago, Duke came to the Champions Classic with a group of highly-touted freshman as the top-ranked team in the nation. The Michigan State Spartans have a National Player of the Year candidate Miles Bridges to star in their lineup.
When he worked with HLC, Grealy said that during deliberations, he was a strong and influential voice for health system transformation to achieve greater value as defined by affordability and consistent clinical quality without disparities. "I don't think it's possible to reform the system unless you truly understand this very complicated system we've created", says Adam Fein, president of Pembroke Consulting.
Patient advocacy organization Public Citizen said Azar has made it clear he is opposed to measures "to restrain prescription companies' profiteering and limit improper marketing" and that he favors weaker safety approval standards. Democrats and other critics are likely to raise questions about the administration's seriousness about lowering drug prices with a former industry executive leading such a charge.
- FDx Advisors Inc. Acquires 10427 Shares of TJX Companies, Inc. (The) (TJX)
- Senate approves Buhari's $5.5bn foreign loan request
- Wells Fargo & Company (WFC) Shares Bought by Deprince Race & Zollo Inc
- GDP up by 0.6% in both euro area and EU28
- Supermarket prices rising at fastest rate in 4 years
- S&P declares Venezuela in default
- Vietnam says fundamental deal reached on trade
- Apple Inc. (AAPL) is NewFocus Financial Group LLC's 3rd Largest Position
- Tennessee State football player sucker punches coach
- High winds, lots of rain in Monday forecast